Clinical trials: Hematologic Tests
Essential Thrombocythemia, Myelofibrosis
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm.
- Conditions
- Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera
- Trial name
- NCT03878199
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Acute Myeloid Leukemia
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
This trial studies the side effects of nivolumab in combination with decitabine and venetoclax and to see how well they work in treating patients with TP53-mutated acute myeloid leukemia.
- Trial name
- NCT04277442
- Testing
- Decitabine, Nivolumab, Venetoclax
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
This phase Ib/II trial studies the effects of ASTX727 (decitabine and cedazuridine) in combination with venetoclax in treating patients with higher-risk acute myeloid leukemia patients who do not have a change in the gene called…
- Trial name
- NCT04817241
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
This phase II MATCH treatment trial tests how well GDC-0449 (vismodegib) works for treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma
- Trial name
- NCT06357988
- Testing
- Biopsy Procedure, Biospecimen Collection, Echocardiography Test
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
This phase II MATCH treatment trial tests how well crizotinib works in treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06357975
- Testing
- Biopsy Procedure, Biospecimen Collection, Crizotinib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Immunodeficiency, Immunosuppression
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce…
- Conditions
- Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease
- Trial name
- NCT05655546
- Testing
- Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- Scripps Translational Science Institute
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
This phase II MATCH treatment trial tests how well larotrectinib (LOXO-101) works in treating patients with cancer that has certain genetic changes.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390852
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
This phase II MATCH treatment trial tests how well ipatasertib works in treating patients with cancer that has certain genetic changes called AKT mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06400251
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
This phase II MATCH treatment trial identifies the effects of afatinib in patients whose cancer has genetic changes called HER2 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439136
- Testing
- Afatinib Dimaleate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer, Rectal Cancer
Prevention of Colorectal Cancer Through Multiomics Blood Testing
The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a…
- Conditions
- Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases
- Trial name
- PREEMPT CRC (NCT04369053)
- Testing
- Freenome test
- Where
- 148 sites in United States, Canada
- Volunteers
- 48,995 people, healthy volunteers welcome
- Sponsor
- Freenome Holdings Inc.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
This phase II MATCH treatment trial tests how well JNJ-42756493 (erdafitinib) works in treating patients with tumors that have more copies of the FGFR gene than is normal (amplification).
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06308822
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Eosinophilic Esophagitis
Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis
Presently, the only method available to monitor disease activity in Eosinophilic Esophagitis (EoE) is endoscopy with pathological review of biopsies.
- Trial name
- NCT03305653
- Testing
- Esophageal String Test (EST)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Colorado, Denver
Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS)
The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss
In the proposed study, the investigators will aim to develop and pilot a Magnetic Resonance (MR) imaging protocol and assess its ability to achieve the following: quantification of tumour burden and bone loss, detecting…
- Conditions
- Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smouldering Myeloma
- Trial name
- LOOMIS (NCT03951220)
- Testing
- Diffusion Weighted Magnetic Resonance Imaging (DWMRI), DXA scan, Bloods and urine
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Oxford University Hospitals NHS Trust
Acute Myeloid Leukemia
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
This phase II trial studies how well nivolumab works in eliminating any remaining cancer cells and preventing cancer from returning in patients with acute myeloid leukemia that had a decrease in or disappearance of signs and…
- Trial name
- NCT02275533
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation
- Where
- 46 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement.
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT02828358
- Testing
- Azacitidine, Biospecimen Collection, Computed Tomography
- Where
- 170 sites in United States, Australia and 2 more
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasm of Large Intestine
Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population
The purpose of this study is to determine if the direct mailing of fecal occult blood testing (FOBT) kits to patients who are due for colorectal cancer screening is an effective way to improve colorectal cancer screening rates…
- Trial name
- NCT01385579
- Testing
- Care manager outreach
- Where
- United States
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
This phase II MATCH treatment trial identifies the effects of palbociclib in patients whose cancer has genetic changes called CCND1, 2, or 3 amplification.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439201
- Testing
- Palbociclib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a complete loss of PTEN expression.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439188
- Testing
- PI3K-beta Inhibitor GSK2636771
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Blood Coagulation Disorders
Clinical and Economic Implications of Genetic Testing for Warfarin Management
The purpose of this study is to explore how knowing genes that individuals inherit from their parents can make warfarin dosing more safe and effective.
- Trial name
- NCT00964353
- Testing
- Warfarin
- Where
- United States
- Volunteers
- 359 people
- Sponsor
- University of Chicago
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
This phase II MATCH treatment trial tests how well afatinib works in treating patients with cancer that has certain genetic changes. Afatinib is in a class of medications called kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06385483
- Testing
- Afatinib, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)